A New Hope for MS? Unpacking Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
For those navigating the challenging landscape of Multiple Sclerosis (MS), the quest for effective treatments often feels unending. While disease-modifying therapies (DMTs) have revolutionized MS care for many, they aren’t a perfect solution. But, for a specific group of individuals with relapsing-remitting MS (RRMS), a potentially transformative treatment is gaining attention: autologous hematopoietic stem cell transplantation (aHSCT).
Understanding aHSCT: Rebooting the Immune System
At its core, aHSCT is a type of bone marrow transplant that aims to “reset” the immune system. In RRMS, the immune system mistakenly attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord. aHSCT seeks to halt these attacks, potentially slowing or even stopping the disease’s progression. The process involves using the patient’s own blood-forming stem cells (“autologous” meaning from the patient, and “hematopoietic” referring to blood cell formation).
This isn’t a brand-new concept. The first attempts at using aHSCT for MS patients were made in the 1990s. Over time, the procedure has become safer and more refined. Research suggests it may offer years of remission for some individuals. Curious about how it works? Let’s break it down.
Pro Tip: aHSCT vs. HSCT
You might see “HSCT” mentioned, which stands for Hematopoietic Stem Cell Transplantation. The “a” in aHSCT specifies that the patient’s own cells are used.
The aHSCT Process: A Step-by-Step Look
As Dr. Jeffrey Cohen, a professor of neurology at the Cleveland Clinic, explains, aHSCT involves a series of steps:
- Stem Cell Collection: Stem cells are released from the bone marrow into the blood, collected via a process similar to dialysis called leukapheresis, and frozen.
- Conditioning (Immune Ablation): Chemotherapy is used to eliminate the misfiring immune cells responsible for MS relapses.
- Stem Cell Infusion: The harvested stem cells are thawed and infused back into the patient to rebuild the immune system.
- Recovery: The immune system gradually recovers, with close monitoring for infections and other potential complications.
This is typically an inpatient procedure, spanning about four to six weeks. After discharge, recovery continues over several months.
Who Might Benefit From aHSCT?
aHSCT isn’t for everyone. Ideal candidates usually have relapsing MS that hasn’t responded well to existing medications. Dr. Cohen notes that good candidates generally have relatively early RRMS, a moderate level of disability, and no significant other health issues.
Conversely, those with long-standing progressive MS, a high level of disability, or other health complications are less likely to benefit and more prone to complications.
Did you know?
The term “relapsing-remitting MS” describes a pattern of attacks (relapses) followed by periods of recovery (remissions). Other types of MS, like primary progressive MS, have a different course.
Efficacy of aHSCT: What the Research Shows
The available data paint a promising picture. Dr. Cohen points to reports of “very marked benefit, very potent efficacy, and very good disease control.” For instance, a recent UK study (the only one so far to use a comparator group) demonstrated that individuals who underwent aHSCT experienced fewer relapses over a five-year period compared to those taking high-efficacy DMTs, such as ocrelizumab (Ocrevus) and alemtuzumab (Lemtrada).
A Swedish study of 174 people who underwent aHSCT before 2020 found that at 5 years, 73% of people had no evidence of disease activity.
However, it’s important to acknowledge that aHSCT isn’t a guaranteed cure. In the UK trial, approximately 10-15% of the transplant group experienced either an attack, a return of attacks, or worsening disability during the five-year follow-up.
Ongoing clinical trials are investigating whether aHSCT could be used earlier in the treatment sequence.
How Long Do the Effects Last? The Question of Durability
A key advantage of aHSCT is the potential for long-term remission. According to Dr. Cohen, many individuals who respond to treatment can go five to ten years or even longer without needing additional MS medications. However, it’s not necessarily a permanent solution; some individuals may eventually experience disease activity and require further treatment.
Safety Concerns: Weighing the Risks
The aHSCT procedure is not without risks. The chemotherapy used to wipe out the immune system leaves patients vulnerable to infections, some of which can be life-threatening. Those who are older, have higher disability levels, or have other health conditions face a greater risk of complications. Close monitoring and supportive care are crucial during the recovery phase.
Availability in the United States: A Growing Trend?
Despite its potential benefits, aHSCT is not yet widely available in the U.S. It’s primarily offered within the context of clinical trials, although some institutions, such as the Cleveland Clinic, may offer it to select patients outside of trials. Centers performing aHSCT need specialized expertise and experience.
Insurance coverage is often handled on a case-by-case basis. While many insurers will consider it, securing coverage frequently requires appeals. At present, routine coverage from most payers is not available.
The Future of aHSCT: Will it Become Mainstream?
The answer is possibly. Ongoing studies, such as the BEAT-MS trial, are comparing aHSCT to the most effective existing medications to analyze efficacy and cost-effectiveness. The National MS Society supports stem cell therapies, with significant investment in research, underlining their commitment.
If trials show aHSCT to be safe and cost-effective, insurance coverage is likely to improve, potentially leading to wider adoption.
FAQ: Your Burning Questions About aHSCT
- Is aHSCT a cure for MS? No, aHSCT is not a guaranteed cure. However, it can lead to long-term remission and reduce the frequency of relapses.
- How long does the aHSCT procedure take? The procedure itself usually takes about four to six weeks. Recovery can take several months.
- Where can I get aHSCT? In the US, it is primarily offered through clinical trials and a limited number of specialized centers.
- Is aHSCT covered by insurance? Coverage varies; often, it requires appeals. Currently, widespread routine insurance coverage is not available.
For more in-depth information, visit the National MS Society website.
Ready to learn more about MS treatments? Explore our other articles on disease-modifying therapies and new advances in MS care. Subscribe to our newsletter for the latest updates delivered directly to your inbox!
